Too much of a good thing?: IRIS with natalizumab-associated PML

Neurology

Volumn 77, Issue 11, 2011, Pages 1033-1034

  Berger, Joseph R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; NATALIZUMAB; VERY LATE ACTIVATION ANTIGEN 4; MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CORTICOSTEROID THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; EXPANDED DISABILITY STATUS SCALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INFLAMMATORY CELL; JC VIRUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SURVIVAL; SURVIVAL RATE; VIRUS LOAD; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; NOTE;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE;

EID: 80155141586     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822e14b7     Document Type: Editorial

References (7)

1. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011;77:1061-1067.
2. Clifford DB, De Luca A, Simpson DM, et al. Natalizumabassociated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-446.
3. Antinori A, Cingolani A, Lorenzini P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003;9(suppl 1):47-53. (Pubitemid 36656471)
4. Falco V, Olmo M, del Saz SV, et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 2008;49:26-31.
5. Biogen Idec. PML incidence in patients receiving Tysabri. Available at: medinfo.biogenidec.com. Accessed April 28, 2011.
6. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005;4:510-518. (Pubitemid 40861993)
7. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab: unforeseen consequences. N Engl J Med 2005;353:414-416. (Pubitemid 41132348)